Dyne Therapeutics Inc logo

Dyne Therapeutics Inc

DYN
Healthcare|Biotechnology|USA
$23.43
-0.84 (-3.48%)
Tangible Book
$5.24
Earnings Power
$4.45

Upcoming Data Readouts (6)

Dec 2027
Est. completion
FSHD
Motor Outcomes to Validate Evaluations in FSHD (MOVE FSHD)
NCT04635891n=450
Dec 2027
Est. completion
Facioscapulohumeral Muscular Dystrophy
Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD
NCT03458832n=324
Jul 2028
Est. completion
P3Myotonic Dystrophy Type 1 (DM1)
Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1
NCT07486934n=150
Jul 2029
Est. completion
P1P2Myotonic Dystrophy Type 1 (DM1)
Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dystrophy Type 1
NCT05481879n=116
Nov 2029
Est. completion
P1P2Duchenne Muscular Dystrophy (DMD)
Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
NCT05524883n=86
Dec 2030
Est. completion
P3Duchenne Muscular Dystrophy (DMD)
Efficacy, Safety, and Tolerability of Zeleciment Rostudirsen (DYNE-251) Administered Intravenously Every 4 Weeks in Ambulatory Participants With Duchenne Muscular Dystrophy (FORZETTO)
NCT07608432n=90

Recent Press Releases